John Heymach, MD, PhD
Advertisement
Articles by John Heymach, MD, PhD
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Advertisement
Latest Updated Articles
Improved Outcomes for Patients With EGFR+ NSCLCPublished: May 21st 2020 | Updated:
Molecular Testing for Newly Diagnosed NSCLCPublished: May 21st 2020 | Updated:
Repeat Testing at Progression of EGFR+ NSCLCPublished: May 21st 2020 | Updated:
Treatment Options for EGFR+ NSCLCPublished: May 21st 2020 | Updated:
Changing Landscape of EGFR+ mNSCLCPublished: May 21st 2020 | Updated:
Practical Implications of the RELAY Trial in EGFR+ NSCLCPublished: May 21st 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5